SCHEMBL25427554

SCHEMBL25427554

COCCOC(=O)c1cc([N+](=O)[O-])n(CCOC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
TSHR P16473 2/20 0.37
GUSB P08236 1/20 0.36
GLA P06280 2/20 0.36
TP53 P04637 1/20 0.35
MAPT P10636 4/20 0.35
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
ALDH1A1 P00352 5/20 0.35
LMNA P02545 3/20 0.35
POLB P06746 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25316013 0.77 ALDH1A1 (0.39) TSHRTP53MAPTMEN1KMT2A
SCHEMBL5813872 0.75 PDE4A (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL19635549 0.74 CNR1 (0.47) CNR1CNR2TSHRTP53MAPT
SCHEMBL21960873 0.72 KMT2A (0.35) CNR1CNR2MAPTMEN1KMT2A
SCHEMBL19616009 0.71 CNR1 (0.42) CNR1CNR2TSHRTP53MAPT
SCHEMBL25428552 0.70 CYP3A4 (0.38) TSHRMAPTMEN1KMT2AALDH1A1
SCHEMBL21960986 0.70 KDM4E (0.36) GUSBMAPTMEN1KMT2AALDH1A1
SCHEMBL26675183 0.70 GAA (0.40) MAPTMEN1KMT2AL3MBTL1HTT
SCHEMBL21964575 0.69 ALDH1A1 (0.43) CNR1CNR2TSHRMAPTMEN1
SCHEMBL23910436 0.69 ALDH1A1 (0.36) MAPTMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK 2023-12-28 US disclosed
EP-4217355-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 Forkhead Biotherapeutics, inc. (US) 2023-08-02 EP disclosed
WO-2022066938-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FORKHEAD BIOTHERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FOXO1, FOXO3, GCKR CNR1 4604/4885CNR2 4708/4885TSHR 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.